Orchestra BioMed Holdings, Inc. (OBIO)

NASDAQ: OBIO · IEX Real-Time Price · USD
5.39
+0.08 (1.60%)
Mar 28, 2024, 1:23 PM EDT - Market open
1.60%
Market Cap 189.62M
Revenue (ttm) 2.76M
Net Income (ttm) -49.12M
Shares Out 35.74M
EPS (ttm) -1.48
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 26,317
Open 5.24
Previous Close 5.31
Day's Range 5.24 - 5.62
52-Week Range 4.26 - 23.39
Beta 0.18
Analysts Strong Buy
Price Target 17.00 (+215.4%)
Earnings Date Mar 27, 2024

About OBIO

Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension; and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a strategic collaboration with Medtronic for the development and commercialization of BackBeat CNT for the treatment of hypertension in pat... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2017
Employees 4
Stock Exchange NASDAQ
Ticker Symbol OBIO
Full Company Profile

Financial Performance

In 2023, OBIO's revenue was $2.76 million, a decrease of -21.88% compared to the previous year's $3.53 million. Losses were -$49.12 million, 46.2% more than in 2022.

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for OBIO stock is "Strong Buy." The 12-month stock price forecast is $17.0, which is an increase of 215.40% from the latest price.

Price Target
$17.0
(215.40% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Orchestra BioMed Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update

NEW HOPE, Pa., March 27, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to pat...

21 hours ago - GlobeNewsWire

Orchestra BioMed Announces Appointment of Medical Device Industry Expert David Pacitti to Board of Directors

NEW HOPE, Pa., March 26, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to pat...

2 days ago - GlobeNewsWire

Orchestra BioMed to Participate in Upcoming Investor Conferences

NEW HOPE, Pa., March 07, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to pat...

21 days ago - GlobeNewsWire

Orchestra BioMed Announces Presentation of Results from Clinical Study Demonstrating Favorable Hemodynamic Effects of AVIM Therapy In Hypertensive Pacemaker Patients

NEW HOPE, Pa., March 06, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to pat...

22 days ago - GlobeNewsWire

Orchestra BioMed Announces Initiation of BACKBEAT Pivotal Study of AVIM Therapy in Hypertensive Pacemaker Patients

NEW HOPE, Pa., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to pati...

2 months ago - GlobeNewsWire

Orchestra BioMed Reports Third Quarter 2023 Financial Results and Provides Business Update

NEW HOPE, Pa., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to pati...

4 months ago - GlobeNewsWire

Orchestra BioMed to Present at Upcoming Investor Conferences

NEW HOPE, Pa., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to pat...

4 months ago - GlobeNewsWire

Orchestra BioMed Granted FDA Approval of IDE to Initiate BACKBEAT Pivotal Study of BackBeat CNT™ for the Treatment of Hypertension in Pacemaker Patients

NEW HOPE, Pa., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to pa...

6 months ago - GlobeNewsWire

Orchestra BioMed Reports Second Quarter 2023 Financial Results and Provides Business Update

NEW HOPE, Pa., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to pati...

8 months ago - GlobeNewsWire

Orchestra BioMed™ Granted FDA Approval of IDE for U.S. Pivotal Study of Virtue® Sirolimus AngioInfusion Balloon™ in Patients with Coronary In-Stent Restenosis

NEW HOPE, Pa., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to pati...

8 months ago - GlobeNewsWire

Orchestra BioMed Set to Join Russell 3000® and other FTSE Russell Indexes

NEW HOPE, Pa., June 26, 2023 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to pati...

9 months ago - GlobeNewsWire

Orchestra BioMed Appoints Bill Little as Executive Vice President of Corporate Development and Strategy and Andrew Taylor as Chief Financial Officer

Bill Little, previously Chief Operating Officer (COO) of Neovasc, Inc. through its acquisition by Shockwave Medical in April 2023, will lead efforts to forge further strategic collaborations in newly ...

10 months ago - GlobeNewsWire

Orchestra BioMed Reports First Quarter 2023 Financial Results and Provides Business Update

NEW HOPE, Pa., May 12, 2023 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patie...

11 months ago - GlobeNewsWire

Orchestra BioMed Announces Upcoming Presentations on BackBeat CNT™ and Virtue® SAB at CRT 2023

NEW HOPE, Pa., Feb. 24, 2023 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to pati...

1 year ago - GlobeNewsWire

Orchestra BioMed Debuts as Nasdaq-Traded Company with Lead Programs Targeting Hypertension and Artery Disease and Novel Partnership-Enabled Business Model

Business combination with Health Sciences Acquisitions Corporation 2, a special purpose acquisition company sponsored by an affiliate of RTW Investments, LP, completed on January 26, 2023

1 year ago - GlobeNewsWire

Orchestra BioMed™ Announces Strategic Collaboration, Closing of $110 Million Private Equity Financing and Plans to List on Nasdaq Through Merger with Health Sciences Acquisitions Corporation 2

Strategic collaboration with Medtronic to develop BackBeat Cardiac Neuromodulation Therapy™ as potential integrated hypertension treatment for cardiac pacemaker patients

1 year ago - GlobeNewsWire